New Hospital Cannabis Laws Are A Step Forward, But Investors Should Temper Expectations

Cannabis policy in 2026 is no longer just about legalization. It is entering a more complicated federal regulatory phase, one shaped less by broad legalization wins than by slow, uneven institutional change.

In the past week, lawmakers in Colorado and Louisiana made headlines for advancing bills that would allow the use of medical cannabis in hospitals and other healthcare settings for terminally ill patients.

While these developments are notable for cannabis investors and industry stakeholders, they should not be mistaken for full healthcare integration.

What Happened?

Colorado’s SB 26-007, signed by Gov. Jared Polis last week, allows terminally ill patients to use medical cannabis in healthcare facilities under certain conditions. However, the bill also lets facilities opt out, meaning access may still depend on the hospital rather than state law, creating a patchwork system.

Gov. Polis raised concerns about that limitation when addressing amendments to the bill from Sen. Kyle Mullica and Reps. Sheila Lieder and Lisa Feret that made participation optional for hospitals.

“I am concerned that many hospitals may not utilize this option, but at least hospitals have a chance to demonstrate otherwise,” Gov. Polis said in a statement.

The Louisiana legislature is advancing a similar policy. The Senate Health and Welfare Committee green-lighted SB 270 with amendments in a voice vote on Wednesday, reported The Marijuana Herald.

The bill from Sen. Katrina Jackson-Andrews is restrictive, requiring hospitals to create policies that prohibit smoking and vaping cannabis while also barring staff from handling or administering it. It was also amended to allow hospitals to opt out if federal authorities take action against any facility in the state over medical cannabis, not just those directly targeted.

The latest legislative changes come about two months after Virginia lawmakers passed bills to expand access to medical marijuana in hospitals and provide legal protections for healthcare workers to administer it to terminally ill patients if federal law changes to reclassify cannabis.

What It Means

Together, these developments point to a deeper issue. Cannabis may be legal medicine in many states, but it still is not fully integrated into the healthcare system.

Patients, especially those in palliative care, may be affected most. Being admitted to a hospital can still mean losing access to a treatment that helps manage pain, nausea or anxiety.

This gap could persist even if cannabis is moved to Schedule III. Rescheduling alone would not create FDA-approved products, standard prescribing pathways or reimbursement mechanisms for most state-legal cannabis products.

The FDA has recently signaled limited flexibility for certain hemp-derived CBD products used in healthcare, saying it would exercise enforcement discretion under narrow conditions, including physician oversight and Medicare-linked distribution. But that policy is tightly scoped and does not change the agency’s broader authority over cannabis or cannabinoid products.

President Donald Trump signed an executive order on December 18, 2025, directing the US attorney general and federal agencies to move expeditiously on cannabis rescheduling and expand research into medical marijuana and cannabidiol. Even so, that action does not by itself resolve the legal and operational barriers hospitals face when it comes to medical cannabis.

For now, cannabis operators and investors should view hospital-use policy changes as an incremental signal rather than an immediate catalyst.

They may point to the long-term normalization of cannabis in healthcare settings, particularly in end-of-life care. But until hospitals can operate under clearer federal protections and the broader legal framework aligns more closely with state systems, the revenue implications are likely to remain limited.